Generics industry complains of EFPIA 'misinformation' on counterfeiting
This article was originally published in Scrip
Executive Summary
In a 10 July letter to the European Commission, the European Generic medicines Association (EGA) has drawn attention to what it calls 'misinformation' emanating from the R&D-based industry association, the European Federation of Pharmaceutical Industries and Associations (EFPIA), on counterfeiting in the generics sector.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.